{Reference Type}: Journal Article
{Title}: Migraine Management in Medically Complex Patients: a Narrative Review.
{Author}: Hird MA;Sandoe CH;
{Journal}: Curr Neurol Neurosci Rep
{Volume}: 24
{Issue}: 9
{Year}: 2024 Sep 29
{Factor}: 6.03
{DOI}: 10.1007/s11910-024-01361-y
{Abstract}: <B>OBJECTIVE: </B>The current review aims to provide an overview of migraine treatment strategies in medically complex patients, including those with renal, liver, and cardiovascular disease.<BR><B>RESULTS: </B>In cardiovascular disease, gepants are likely safe for acute therapy; NSAIDs, ergotamines, and triptans are not recommended. Beta-blockers, ACEi/ARBs, and verapamil have potential cardiovascular benefits in addition to migraine preventive benefit. Frovatriptan requires no dose adjustments in kidney disease or in mild to moderate liver disease. Gepants are safe acute and preventive treatment options in mild and moderate renal and hepatic disease. TCAs and valproic acid require no dose adjustments in renal disease. OnabotulinumtoxinA is likely safe in cardiac, renal, and hepatic impairment. Although CGRP monoclonal antibodies are likely safe in renal and hepatic disease, further study is needed in these conditions as well as in cardiac disease, and no dosing recommendations are available. Effective options are available for those with complex medical comorbidities. Further research is required on the safety of newer migraine-specific therapies in these complex populations.